AstraZeneca and Ironwood announce linaclotide collaboration for China

Tuesday, 23 October 2012

AstraZeneca and Ironwood Pharmaceuticals, Inc. announced today an agreement to co-develop and co-commercialise Ironwood’s linaclotide in China. Linaclotide is the first and only guanylate cyclase-C (GC-C) agonist approved by the US Food and Drug Administration, in August, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

Read the full press release

Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar